	US 12,103,954 B2
	Heterodimeric Fc cytokines and uses thereof
Patrick Lupardus, Menlo Park, CA (US); and Deepti Rokkam, Sunnyvale, CA (US)
Assigned to Synthekine, Inc., Menlo Park, CA (US)
Filed by Synthekine, Inc., Menlo Park, CA (US)
Filed on Feb. 20, 2024, as Appl. No. 18/582,180.
Application 18/582,180 is a continuation of application No. 18/516,047, filed on Nov. 21, 2023.
Application 18/516,047 is a continuation of application No. PCT/US2022/078465, filed on Oct. 20, 2022.
Claims priority of provisional application 63/257,913, filed on Oct. 20, 2021.
Prior Publication US 2024/0209049 A1, Jun. 27, 2024
Int. Cl. C07K 14/54 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC C07K 14/5434 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 38/00 (2013.01)]

15 Claims

1. A heterodimeric hIL12Fc mutein, the heterodimeric hIL12Fc mutein comprising a first polypeptide having the sequence of any one of SEQ ID NOS: 80, 83, 85, 86, 88, 90, 92, 121, 129, 132, 135, 138, 141, 144, 147, 150, and 153; and

a second polypeptide having the sequence of any one of SEQ ID NOS: 81, 82, 84, 87, 89, 91, 93, and 124.